Blood Platelet Plasminogen Activator Inhibitor: Two Different Pools of Endothelial Cell Type Plasminogen Activator Inhibitor in Human Blood

Summary

An assay for plasminogen activator inhibitor in human platelets is described. With this assay we find an average value of 6.8 × 10⁻⁸ IU/platelet (S.D. = 3.0 × 10⁻⁸; n = 20) in a healthy population. We characterized the PA-inhibitor from platelets and identified it as endothelial cell type plasminogen activator inhibitor, by its immunologic and functional properties. Besides the plasma pool of plasminogen activator inhibitor with a very high turnover rate, platelets constitute a second pool of plasminogen activator inhibitor in the circulation of the same order of magnitude. The two different pools of plasminogen activator inhibitor might have a different physiologic function.

Keywords

Fibrinolysis - Platelets - Plasminogen activator inhibitor Summary

• References

• 1 Emeis JJ, Brommer EJ P, Kluft C, Brakman P. Progress in fibrinolysis. In Recent Adv Blood Coagulation Poller L. (Ed) 11-33 Churchill Livingstone; Edinburgh: 1985
• 2 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1983; 43: 77-89
• 3 Danø K, Andreasen PA, Grøndahl-Handen I, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv in Cancer Res 1985; 44: 139-266
• 4 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor of plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 5 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
• 600 Wiman B, Chmielewska I, Rånby M. Inactivation of tissue plasminogen activator in plasma. J Biol Chem 1984; 259: 3644-3647
• 7 Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Biochim Biophys Acta 1984; 802: 111-118
• 8 Juhan-Vague I, Moerman B, De Cock F, Ailland MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
• 9 Korninger C, Wagner O, Binder BR. Tissue plasminogen activator inhibitor in human plasma: Development of a functional assay system and demonstration of a correlating M_r = 50,000 antiactivator. J Lab Clin Med 1985; 105: 718-724
• 10 Sprengers ED. A sensitive assay, specific for endothelial cell type plasminogen activator inhibitor in blood plasma. Thromb Haemostas 1986; 55: 74-77
• 11 Golder JP, Stephens RW. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators. Eur J Biochem 1983; 136: 517-522
• 12 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterisation of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-1472
• 13 Booth NA, Anderson JA, Bennett B. Platelets release protein which inhibits plasminogen activators. J Clin Pathol 1985; 38: 825-830
• 14 Holmberg L, Lecander I, Persson B, Åstedt B. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. Biochim Biophys Acta 1978; 544: 128-137
• 15 Wijngaards G. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Thromb Haemostas 1979; 41: 590-600
• 16 Lecander I, Roblin R, Åstedt B. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Brit J Haematol 1984; 57: 407-412
• 17 Dosne AM, Dupuy E, Bodevin E. Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res 1978; 12: 377-387
• 18 Esnard F, Dupuy E, Dosne AM, Bodevin E. Partial characterization of a fibrinolytic inhibitor produced by cultured endothelial cells derived from human umbilical vein. Thromb Haemostas 1982; 47: 128-131
• 19 Emeis JJ, Van Hinsbergh VW M, Verheijen JH, Wijngaards G. Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells. Biochem Biophys Res Comm 1983; 110: 392-398
• 20 Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804-6808
• 21 Loskutoff DJ, Van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-2960
• 22 Sprengers ED, Verheijen JH, Van Hinsbergh VW M, Emeis JJ. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta 1984; 801: 163-170
• 23 Philips M, Juul A, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984; 802: 99-110
• 24 Van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (anti-activator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-14921
• 25 Sprengers ED, Princen HM G, Kooistra T, Van Hinsbergh VW M. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985; 105: 751-758
• 26 Thorsen S, Brakman P, Astrup T. Influence of platelets on fibrinolysis. A critical review. In Hematologic Reviews. Vol 3 Ambrus JL. (ed) Marcel Dekker; New York: 1972: 123-179
• 27 Ludlam CA, Cash JD. Studies on the liberation of β-thromboglobulin from human platelets in vitro. Brit J Haematol 1976; 33: 239-247
• 28 Walsh PN. Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities. Brit J Haematol 1972; 22: 205-217
• 29 Kluft C, Van Wezel AL, Van der Velden CA M, Emeis JJ, Verheijen JH, Wijngaards G. Large-scale production of extrinsic (tissue-type) plasminogen activator from human melanoma cells. In Advances in Biotechnological Processes Mizrahi A, Van Wezel AL. (Eds) Alan R Liss; New York: 1983. 2 97-110
• 30 Gaffney PJ, Curtis AD. A collaborative study of a proposed international standard for tissue-type plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
• 31 Verheijen JH, Sprengers ED, Emeis JJ, Van Hinsbergh VW M, Chang GT G, Kluft C. Tissue-plasminogen activator inhibition by human endothelial cell conditioned medium and plasma. In Progress in Fibrinolysis VII Davidson JF, Donati MB, Coccheri S. (Eds) Churchill Livingstone; Edinburgh: 1985: 141-145
• 32 Laemmli UK. Cleavage of structural proteins during the assembly of the head of backriophage T4. Nature 1970; 277: 680-685
• 33 Sprengers ED, Van Hinsbergh VW M, Jansen BG. Relationship between the fast-acting and the latent plasminogen activator inhibitor, secreted by human endothelial cells. Thromb Haemostas 1985; 54: 299 (Abstr)
• 34 Barlow RB. Biodata handling with microcomputers. 1983: 12-15 Elsevier Science Publishers;
• 35 Kluft C, Jie AF H, Sprengers ED, Verheijen JH. Identification of a reversible inhibitor of plasminogen activators in blood plasma. FEBS Letters 1985; 190: 315-318
• 36 Van Hinsbergh VW M, Bertina RM, Van Wijngaarden A, Van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-451
• 37 Colucci M, Paramo JM, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1984; 75: 818-824